Insomnia – Prevalence, Diagnosis and Latest treatment for Sleeplessness

Print pagePDF pageEmail page

Background

If you have difficulty failing asleep, frequent awakenings, early morning awakenings, daytime drowsiness, snoring, or sleep apnea, you might be suffering from insomnia.

Insomnia is a common problem in the US with over 50 million Americans reported having a sleep-related problem.  It occurs more frequently in women, especially postmenopausal women, and in the elderly.  Other factors that predispose a person to have insomnia include snoring and co-morbid psychiatric or medical illnesses.

Diagnosis

Diagnosing insomnia requires a thorough medical history and a physical examination.  The thorough medical history is needed to find out any behaviors such sleep habits, drug and alcohol consumption, nicotine and caffeine intake, co-morbid illnesses and sleep environment that contribute to insomnia, while a complete physical examination is used to rule out any medical conditions such as depression.

Non-pharmacologic interventions

Your physicians might first recommend non-pharmacologic interventions for you.  These non-pharmacologic interventions might include 1) sleep-hygiene education, 2) stimulus-control therapy, 3) relaxation therapy, and 4) sleep-restriction therapy, collectively referred to as Cognitive Behavioral Therapy (CBT).

1) Sleep-hygiene education includes:

–         Maintaining a regular sleep schedule

–         Exercising regularly but avoiding exercise too close to bed-time

–         Avoiding stimulants like caffeine or nicotine right before bed-time.

–         Ensuring a comfortable sleep environment (i.e., eliminate noises, decrease light, and maintain a comfortable room temperature)

–         Avoiding negative thinking or focusing on a bedside clock.

2) Stimulus-control therapy focuses on establishing an association between bed and sleep.  This includes:

–         Going to bed only when tired

–         Use the bedroom only for sleeping

–         Establish a normal sleep-wake schedule, and avoid napping.

–         Leave the bedroom if unable to fall asleep within 15 minutes and to return to bed only when tired.

3) Relaxation therapy includes progressive muscle relaxation, biofeedback, and meditation.

4) Sleep restriction therapy allows patients to improve sleep efficiency by temporarily inducing sleep deprivation.

About 50% to 80% of the patients respond to the above therapies.  Stimulus control and sleep restriction are the most effective non-pharmacologic interventions.

Prescription Agents

If non-pharmacological therapies do not work, your physicians might prescribe hypnotics for you.  The three most common classes of hypnotics are benzodiazepines, benzodiazepines-receptor agonist and melatonin-receptor agonists.

Continue reading

Posted in Insomnia | Tagged , , , , , , , , , , , , , , , , , , | Comments Off on Insomnia – Prevalence, Diagnosis and Latest treatment for Sleeplessness

Should you continue to take Statin if it Increases the Risk of Diabetes?

Print pagePDF pageEmail page

In the February issue of Lancet, Sattar and his colleagues presented a meta-analysis of 13 large, placebo-controlled trials, in which they discovered statin users have a higher risk of developing diabetes. 

The analysis involved 91,000 individuals and the results indicated that statin users were associated with a slight (9%) increase in risk of developing diabetes.  The increase in risk of diabetes was found mostly in older patients and the increase in risk was not associated with body-mass index or changes in LDL cholesterol.

So, should you discontinue your statin therapy?

To put this result into perspectives, it is important to note that other cardiovascular drugs have also been associated with an increase in the risk of developing diabetes.  These drugs include diuretics, beta-blockers and niacin.

Furthermore, Sattar and colleagues calculated that one extra case of diabetes occurred for every 255 patients treated with statin over four years.  However, 5.4 deaths or myocardial infarction and 5 cases of stroke or coronary revascularization procedures would be avoided over the same period.   Therefore the benefits of taking statins seem to greatly outweigh the risk by a ratio of 9:1 in favor of taking statins.  

Even though you should continue taking your statins (rosuvastatin(Crestor), atorvastatin(Lipitor), simvastatin(Zocor), lovastatin(Mevacor), pravastatin(Pravachol), fluvastatin(Lescol)), it is important to ask your physicians to also monitor your glucose level, in addition to liver-function and creatine kinase monitoring, during your routine check-up. 

Sattar et.al.  Lancet (02/27/10) Vol. 375, No. 9716, P. 735

Please visit us at healthreason.com

Posted in Cardiovascular disease, Diabetes, High cholesterol | Tagged , , , , , , , , | Comments Off on Should you continue to take Statin if it Increases the Risk of Diabetes?

Moderate Drinking in Women Linked to Less Weight Gain

Print pagePDF pageEmail page

Based on the results of study published in the March 8 issue of the Archives of Internal Medicine, normal-weight women who consume light to moderate amounts of alcohol appear to gain less weight and have less risk for obesity than nondrinkers.

The study included 19,220 US women aged 38.9 years or older who had a normal baseline body mass index of less than 25 kg/m2 and did not have any underlying disease. The investigators looked the relationship between alcohol intake and their weight gain during a 13 years follow-up.

To their surprise, they found that alcohol consumption was inversely related to weight gain. The relative risk of becoming overweight or obese was 1.00 for total alcohol intake of 0; then 0.96 for more than 0 to less than 5 g/day; 0.86 for 5 to less than 15 g/day; 0.7 for 15 to less than 30g/day; and 0.73 for 30 g/day or more.

The inverse relationship between alcohol intake and risk of overweight or obesity was found in all types of alcoholic beverages (red wine, white wine, beer and liquor), but it was strongest in red wine and weakest in white wine.

Since drinking alcohol related to lots of psychosocial and medical issues, the investigator cautioned individuals, who wish to consider drinking light to moderate amount of alcohol to control weight gain, to evaluate the risks and benefits of the drinking behavior.

Arch Intern Med. 2010;170(5):453-461.

Please visit us at healthreason.com

Posted in Obesity | Tagged , , , , | Comments Off on Moderate Drinking in Women Linked to Less Weight Gain

Coffee Lower the Risk of Arrhythmia?

Print pagePDF pageEmail page

Coffee drinkers who have been drinking coffee for a long time have another reason to continue their drinking habit.

 A new study presented in the Cardiovascular Disease Epidemiology and Prevention and Nutrition, Physical Activity, and Metabolism 2010 Conference indicated that people who drank coffee were associated with lower risk of having arrhythmia.

The researcher studied the eating and drinking habits of 130,054 participants in the Kaiser Permanente health plan and their incidence of cardiovascular diseases.  The researchers found that people who drank coffee have a lower risk of getting arrhythmia. 

Furthermore the more coffee they drank, the greater the protection.  For example, individuals who drank 1-3 cups of coffee per day had 7% lower risk of being hospitalized for any arrhythmia, while individuals who dank more than 4 cups per day have 18% lower risk.

The researchers also looked at the risk reduction among individuals who drank decaffeinated coffee, but found no protective effects, which indicates caffeine played a major role.

At present, the researchers do not know the exact mechanisms of the protective effect, but believe it is related to the inhibitory effect of caffeine on a compound, adenosine, that stimulates arrhythmia.

Please visit heathreason.com

Hasan AS et. al.  EPI/PNAM 2010; March 2-5, 2010, San Francisco, CA.  Abstract P461.

Posted in Arrhythmia, Cardiovascular disease | Tagged , , | Comments Off on Coffee Lower the Risk of Arrhythmia?

Atrial Fibrillation – Causes, Symptoms, Diagnosis, Prognosis and Latest Treatment

Print pagePDF pageEmail page

If you have heart beat that is quicker than 60-80 beats per minute at rest or 90-115 beats per minutes during exercise, you might have fast and irregular heart beat or arrhythmia.    There are different kinds of arrhythmia but atrial fibrillation (AF) is the most common type 

Causes

AF occurs when more than one cardiac cell in the upper chamber (atrial) of your heart are beating.  This usually occurs in patients who have pre-existing cardiovascular diseases (secondary AF) such as coronary artery disease, cardiac surgery, hypertension, myocardial infarction, valve disorders (e.g. mitral valve disease) and congestive heart failure.  The changes in cardiac structure associated with these diseases have damaged the conduction pathway of the cardiac muscle, making AF more prone to happen.

There are, however, some instances where there is no evidence of underlying disease and AF occurs spontaneously.  These are termed “lone AF” and happened in approximately 20% of AF patients. 

CaveSymptoms

Beside a quicker heart rate, patients with AF also experience palpitations, chest pain, dyspnea, fatigue or light-headedness.

Diagnosis and Prognosis

The only way to find out whether you have AF is by conducting an ECG test.  Patients who have arrhythmia will find their P wave absence and their R-R interval shorten in their ECG.

The good news about AF is that it is not life-threatening, but patients with long-term AF occurrence can lead to stroke and heart failure.  In fact, patients with AF have a double risk of death, a 5-fold increase in stroke and a 3-fold increase in heart failure compared with those who do not have AF.

Treatment

Depending on your clinical situation (whether you have hypertension, diabetes or stroke or heart failure), your doctor might prescribe warfarin (Coumadin) or aspirin to prevent stroke and prescribe anti-arrhythmic drugs to slow down your heart rate and convert your heart into rhythm again. Continue reading

Posted in Arrhythmia, Cardiovascular disease | Tagged , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

Best Regimen Sequence for Early Breast Cancer patients

Print pagePDF pageEmail page

Which is the best chemotherapy adjuvant regimen sequence for early breast cancer?

It is widely known that anthracyclines (epirubicin and doxorubicin) and taxanes is the best adjuvant chemotherapy regimen for early breast cancer. However, should anthracyclines be always administered before taxanes? An article published in the March issue of Lancet Oncology suggested the reverse sequence may be more preferable.

The article, written by Wildiers, provided clear evidences that the taxane-first regimens provided better dose intensity, adverse effects, long-term resistance and survival.

1) Dose Intensity

In a dose sequencing study of 284 patients who first received three cycles of FEC (fluorouracil, epirubicin, and cyclophosphamide) followed by three cycles of docetaxel, the mean relative dose intensity was 91% for FEC and 76% for docetaxel, whereas in another dose sequencing study of 378 patients who received three cycles of docetaxel followed by four cycles of EC (epirubicin plus cyclophosphamide), a median docetaxel dose intensity of 100% was achieved.

2) Adverse effects

Studies have showed that patients who were started with taxane-first adjuvant regimens have fewer skins and grade 4 toxicities. Also, data form the FinHer Trial suggested that the incidence of cardiotoxicity was lower when taxane plus trastuzumab (Herceptin) was given before rather than after anthracyclines.

3) Long-term resistance

An in-vitro study showed that breast cancer cells that were initially resistant to paclitaxel have limited cross-resistance (4 times) to doxorubicin whereas cell lines that were resistant to doxorubicin, exhibited a 4,700-times cross-resistance to paclitaxel.

4) Survival

In a large phase 3 neoadjuvant study, paclitaxel administered before epirubicin-cyclophosphamide (EC) showed a higher complete responses rate than the reverse order.

The above evidences indicated that it is reasonable to administer taxane cycles before anthracycline-containing chemotherapy cycles in the routine clinical setting.

www.thelancet.com/oncology Vol 11 March 2010

Visit us at healthreason.com.

Posted in Breast cancer, Cancer | Tagged , , , , , , , | Comments Off on Best Regimen Sequence for Early Breast Cancer patients

Lose Weight, regardless of Diet Intervention, can Shrink the Plague in Carotid Artery

Print pagePDF pageEmail page

A study published in the March issue of the Circulation indicated that people who lost weight by one of the three diets 1) low fat, 2) Mediterranean or 3) low carbohydrate can have the plagues in their carotid artery (the big artery that goes to the brain) reduced.

In a randomized trial conducted over two years, investigators looked at the impact of the above 3 diets on the shrinkage and progression of carotid plague in 140 overweight or obese people with type 2 diabetes or established coronary heart disease.

Over the 2 years, the investigators found that all 3 diets were equally effective at promoting weight lost and blood pressure reduction. Furthermore, the diets also resulted in diminishing the vessel-wall volumes and reducing the plague in the carotid artery. The reduction in plagues was believed to be due to the reduction in blood pressure associated with weight loss.

Since the presence of plagues in the carotid artery suggests atherosclerotic disease, this study also suggests that diet intervention can reduce the risk of atherosclerotic disease.

Shai I. et. al. Dietary intervention to reverse carotid atherosclerosis. Circulation 2010; DOI:10.1161/CIRCULATIONAHA.109.879254.  Available at http://circ.ahajournals.org

Visit us at healthreason.com

Posted in Cardiovascular disease, High cholesterol, Hypertension, Weight loss | Tagged , , , | Comments Off on Lose Weight, regardless of Diet Intervention, can Shrink the Plague in Carotid Artery

Cancer Protective Benefits of Bisphosphonates

Print pagePDF pageEmail page

Patients who are taking bisphosphonates products (Fosamax, Actonel and Boniva) might have a lower risk of getting breast cancer.

A study published in the February issue of the British Journal of Cancer looked at the consumption of bisphosphonate products in 2,936 patients with invasive breast cancer and 2,975 patients without breast cancer. Using statistic analysis, the investigators found that patients who took bisphosphonate products have a reduced risk of getting breast cancer.   Furthermore, the longer the patients took the product, the greater the reduction in breast cancer risk.

Since this was only a retrospective, statistical analysis, a prospective, head-to-head, placebo-controlled trial is needed to confirm this finding.

Newcomb PA et.al. British Journal of Cancer (2010) 102, 799-802

Please visit us at healthreason.com

Posted in Breast cancer, Cancer | Tagged , | Comments Off on Cancer Protective Benefits of Bisphosphonates

Alternative Treatment Options for Late Stage Lung Cancer Patients

Print pagePDF pageEmail page

Paclitaxel plus carboplatin(PC) is the current standard regimen for advanced or metastatic non-small-cell lung cancer (NSCLC) patients.  However, paclitaxel is associated with serious toxicity such as peripheral neuropathy.

A tria,l published in October version of the Annals of Oncology, was conducted to see whether there are other regimens that can deliver the same efficacy as Paclitaxel plus carbopltain, but with better tolerability profile. 

The study included 1,135 chemonaive patients with stage IIIB or IV NSCLC assigned to receive either 1) paclitaxel plus carboplatin(PC), 2) gemcitabine (Gemzar) plus carboplatin(GC) or 3) gemcitabine (Gemzar) plus paclitaxel(GP).

The results indicated that the alternative treatment regimens (GP and GC) resulted in similar survival (8.5 months for GP and 7.9 months for GC) as the standard treatment (8.7 months for PC).  The GP regimen, however, was associated with fewer neutropenia and neuropathy than the standard PC treatment (neutropenia: 20% vs. 34.7% and neuropathy 6.5% vs. 10.9%).  Incidence of alopecia did not differ between the GP and the PC regimen (52.7% vs. 52.7%).

Patients who have late stage NSCLC can now consider GP regimen if they are able to tolerate the alopecia side-effect.

Treat JA  et. al.  Annals of Oncology 21; 540-547, 2010

Please visit us at healthreason.com

Posted in Cancer, Lung Cancer | Tagged , , , , , , , , | Comments Off on Alternative Treatment Options for Late Stage Lung Cancer Patients

New Drug Offer Hope to Patients with Late Stage Prostate Cancer

Print pagePDF pageEmail page

At present, metastatic and hormonal-refractory prostate cancer patients who have failed 1st line chemotherapy will be given mitoxantrone plus prednisone as the salvage therapy.  However, mitoxantrone plus prednisone is not very effective in controlling metastatic prostate cancer.  Now, a new drug developed by sanofi-aventis might offer hope to patients who have failed 1st line chemotherapy (docetaxel plus prednisone).

The new drug called cabazitaxel was investigated in the TROPIC trial that included 755 advanced prostate cancer patients who have failed 1st line docetaxel chemotherapy.  Half of the patients in the trial received combination of cabazitaxel and prednisone while the other half received mitoxantrone and prednisone.

After one year of treatment, men in the cabazitaxel arm had an overall median survival of 15.1 months, compared to 12.7 months among men in the mitoxantrone arm.  Cabazitaxel was also associated with a 30 percent reduced risk of dying.

Like other chemotherapies, cabazitaxel was associated with side-effects such as low white blood cells (81.7%), low white blood cells with fever (7.5%), diarrhea (6.2%) and infections (10.2%).

This drug has not been approved by FDA, but is under the fast track approval process.  To participate in clinical trials, you may visit www.clinicaltrials.gov for details.

http://en.sanofi-aventis.com/binaries/20100304_Asco_GU_en_tcm28-27547.pdf

Please visit us at healthreason.com

Posted in Cancer, Prostate cancer | Tagged , , | Comments Off on New Drug Offer Hope to Patients with Late Stage Prostate Cancer